Advertisement

Neonatology pp 1015-1020 | Cite as

Lung Diseases: Problems of Steroid Treatment of Fetus and Newborn

  • Henry L. Halliday
Reference work entry

Abstract

Corticosteroids given in the perinatal period have a multitude of biologic effects on the developing lung. Clearly, some of these will be beneficial to the immature fetus or neonate, while others will be detrimental. For the fetus at risk of preterm birth, a single course of betamethasone or dexamethasone leads to lung maturity and reduces the risk of RDS and other important complications of prematurity. Consensus seems to support repeat courses of prenatal steroids when there is a high risk of preterm birth before 29 weeks’ gestation even if there are some controversies. The beneficial pulmonary effects of early postnatal dexamethasone, in the first week of life, do not seem to outweigh the adverse effects on neurodevelopment. However, late postnatal steroid therapy, after the first week of life, seems to be associated with similar beneficial pulmonary effects without significant increase in neurodevelopmental sequelae. Late steroid therapy with dexamethasone is probably still indicated for preterm infants with CLD who cannot be weaned from ventilation. Thus, administration of corticosteroids in the perinatal period must be based upon clinical judgment of the balance of benefits and risks. Further evaluation should be done considering long-term follow-up in order to confirm their safety before they can be recommended for routine use.

References

  1. Avery ME, Mead J (1959) Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 97:517–523Google Scholar
  2. Avery GB, Fletcher AB, Kaplan M et al (1985) Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics 75:106–111PubMedGoogle Scholar
  3. Azad C, Costello A (2014) Extreme caution is needed before scale-up of antenatal corticosteroids to reduce preterm deaths in low-income settings. Lancet Glob Health 2:e191–e192CrossRefGoogle Scholar
  4. Baden M, Bauer CR, Colle E et al (1972) A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics 50:526–534PubMedGoogle Scholar
  5. Bassler D, Plavka R, Shinwell ES et al (2015) Early inhaled budesonide for the prevention of bronchopulmonary dysplasia. N Engl J Med 373:1497–1506CrossRefGoogle Scholar
  6. Baud O, Maury L, Lebail F et al (2016) Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. Lancet 387: 1827–1836CrossRefGoogle Scholar
  7. Brownfoot FC, Gagliardi DI, Bain E et al (2013) Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 8, CD006764Google Scholar
  8. Crowther CA, Harding JE, Middleton PF et al (2013) Australasian randomized trial to evaluate the role of maternal intramuscular dexamethasone versus betamethasone prior to preterm birth to increase survival free of childhood neurosensory disability. BMC Pregnancy Childbirth 13:104CrossRefGoogle Scholar
  9. Crowther CA, McKinlay CJ, Middleton et al (2015) Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving health outcomes. Cochrane Database Syst Rev 7, CD003935Google Scholar
  10. Dalziel SR, Lim VK, Lambert A et al (2005) Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ 331:665–668CrossRefGoogle Scholar
  11. Dalziel SR, Crowther CA, Harding JE (2014) Antenatal steroids 40 years on: we can do better. Lancet 384:1829–1831CrossRefGoogle Scholar
  12. Doyle LW, Ehrenkranz RA, Halliday HL (2010) Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 98:111–117CrossRefGoogle Scholar
  13. Doyle LW, Ehrenkranz RA, Halliday HL (2014a) Early (<8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 5, CD001146Google Scholar
  14. Doyle LW, Ehrenkranz RA, Halliday HL (2014b) Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 5, CD001145Google Scholar
  15. Doyle LW, Halliday HL, Ehrenkranz RA et al (2014c) An update on the impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk of bronchopulmonary dysplasia. J Pediatr 165:1258–1260CrossRefGoogle Scholar
  16. Fitzhardinge PM, Eisen A, Lejtenyi C (1974) Sequelae of early steroid administration to the newborn infant. Pediatrics 53:877–883PubMedGoogle Scholar
  17. Grier DG, Halliday HL (2004) Effects of glucocorticoids on fetal and neonatal lung development. Treat Respir Med 3:295–306CrossRefGoogle Scholar
  18. Halliday HL (2011) Postnatal steroids: the way forward. Arch Dis Child Fetal Neonatal Ed 96:F158–F159CrossRefGoogle Scholar
  19. Liggins GC (1968) Premature parturition after infusion of corticotrophin or cortisol into foetal lambs. J Endocrinol 42:323–329CrossRefGoogle Scholar
  20. Liggins GC, Howie RN (1972) A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in preterm infants. Pediatrics 50:515–525PubMedGoogle Scholar
  21. Mammel MC, Green TP, Johnson DE et al (1983) Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet 1:1356–1358CrossRefGoogle Scholar
  22. Peltoniemi OM, Lano A, Yliherva A, Kari MA, Hallman M, Neonatal Hydrocortisone Working Group (2016) Randomised trial of early neonatal hydrocortisone demonstrates potential undesired effects on neurodevelopment at preschool age. Acta Paediatr 105:159–164Google Scholar
  23. Roberts D, Dalziel S (2006) Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 3, CD004454Google Scholar
  24. Sotiriadis A, Tsiami A, Papatheodoros S et al (2015) Neurodevelopmental outcome after a single course of antenatal steroids in children born preterm: a systematic review and meta-analysis. Obstet Gynecol 125:1385–1396CrossRefGoogle Scholar
  25. Sweet DG, Carnielli V, Greisen G et al (2013) European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants – 2013 update. Neonatology 103:353–368CrossRefGoogle Scholar
  26. Taeusch HW Jr, Wang NS, Baden M et al (1973) A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome: II. Pathol Pediatr 52:850–854Google Scholar
  27. Vogel JP, Souza JP, Gulmezoglu AM et al (2014) Use of antenatal corticosteroids and tocolytic drugs in preterm births in 29 countries: an analysis of the WHO Multicountry Survey on Maternal and Newborn Health. Lancet 384:1869–1877CrossRefGoogle Scholar
  28. Wapner R, Jobe AH (2011) Controversy: antenatal steroids. Clin Perinatol 38:529–545CrossRefGoogle Scholar
  29. Yeh TF, Lin YJ, Huang CC et al (1998) Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics 101, e7CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Formerly Regional Neonatal UnitRoyal Maternity HospitalBelfastUK
  2. 2.Formerly Department of Child HealthQueen’s University BelfastBelfastUK

Personalised recommendations